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Background: This study aimed to evaluate the incremental prognostic value of infarct size, microvascular
obstruction (MO), myocardial salvage index (MSI), and left ventricular ejection fraction (LV-EFCMR) assessed by
cardiac magnetic resonance imaging (CMR) in comparison to traditional outcome markers in patients with
ST-elevation myocardial infarction (STEMI) reperfused by primary percutaneous intervention (PCI).
Methods: STEMI patients reperfused by primary PCI (n = 278) within 12 hours after symptom onset underwent
CMR three days after the index event (interquartile range [IQR] two to four). Infarct size and MO were measured
15 minutes after gadolinium injection. T2-weighted and contrast-enhanced CMR were used to calculate MSI. In
addition, traditional outcome markers such as ST-segment resolution, pre- and post-PCI Thrombolysis In Myocardial
Infarction (TIMI)-flow, maximum level of creatine kinase-MB, TIMI-risk score, and left ventricular ejection fraction
assessed by echocardiography were determined in all patients. Clinical follow-up was conducted after 19 months
(IQR 10 to 27). The primary endpoint was defined as a composite of death, myocardial reinfarction, and congestive
heart failure (MACE).
Results: In multivariable Cox regression analysis, adjusting for all traditional outcome parameters significantly
associated with the primary endpoint in univariable analysis, MSI was identified as an independent predictor for
the occurrence of MACE (Hazard ratio 0.94, 95% CI 0.92 to 0.96, P <0.001). Further, C-statistics comparing a model
including only traditional outcome markers to a model including CMR parameters on top of traditional outcome
markers revealed an incremental prognostic value of CMR parameters (0.74 versus 0.94, P <0.001).
Conclusions: CMR parameters such as infarct size, MO, MSI, and LV-EFCMR add incremental prognostic value above
traditional outcome markers alone in acute reperfused STEMI.
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ST-elevation myocardial infarction (STEMI) remains a
common cause of death worldwide. Although mortality
in the acute phase has declined in recent years, partly
due to rapid reperfusion by primary percutaneous coron-
ary intervention (PCI), longterm prognosis remains poor
[1]. Early identification of patients at high risk for adverse
clinical outcome ideally followed by intensification of
therapeutic measures offers the potential to improve prog-
nosis. In clinical routine, risk stratification is commonly
performed using echocardiographic, electrocardiographic,
laboratory, and angiographic parameters or established
risk scores [2-5]. These outcome markers are relatively
easy to obtain, requiring only moderate financial and
human resources. Cardiac magnetic resonance imaging
(CMR) offers a variety of markers such as infarct size,
microvascular obstruction (MO), and myocardial salvage
index (MSI). These CMR parameters have been shown to
be robust predictors of adverse clinical outcome in mid-
sized single center studies [6-9], but are not commonly
incorporated in classic models of clinical risk assessment.
Moreover, left-ventricular ejection fraction assessed by
CMR (LV-EFCMR) might lead to more accurate results
in comparison to assessment by echocardiography [10,11].
However, due to significant costs and requirements in term
of infrastructure and personnel resources, acquisition of
these CMR-derived markers in a purely clinical setting
would only be justified if CMR parameters offered an add-
itional prognostic value above traditional outcome parame-
ters. If so, CMR might allow for an improved identification
of patients at high risk for recurrent cardiovascular events,
influencing further clinical management. However, the
prognostic value of CMR-derived parameters in compa-
rison to a detailed set of traditional non-CMR markers
including left-ventricular ejection fraction determined by
echocardiography (LV-EFecho), enzymatic infarct size, and
the Thrombolysis In Myocardial Infarction (TIMI)-risk
score assessed in clinical routine, has not yet been investi-
gated. The aim of the current study was therefore to eva-
luate a potential incremental prognostic value of CMR
parameters such as infarct size, MO, MSI, and LV-EFCMR
in comparison to traditional outcome markers in a large
cohort of patients with STEMI reperfused by PCI.
Methods
Patients and design
Data from 512 consecutive STEMI patients undergoing
primary PCI at our tertiary care center were analyzed.
Inclusion criteria were the presence of symptoms for less
than 12 hours and ST-segment elevation in more than
or equal to two leads with more than or equal to 0.2 mV
in precordial or more than or equal to 0.1 mV in extrem-
ity leads. Patients with prior fibrinolysis, prior myocardial
infarction, and contraindications to CMR at study entrywere excluded. The current retrospective analysis is based
on patients that were in part initially enrolled in the
LIPSIA N-ACC trial investigating the impact of high-
dose N-acetylcysteine on MSI and the LIPSIA-STEMI
trial investigating the impact of pre-hospital initiated
facilitated PCI versus primary PCI on infarct size and
MSI [12,13]. The LIPSIA N-ACC trial was negative as
the intervention did not result in an improved reper-
fusion success. Further, patients of the LIPSIA-STEMI
trial included in the current analysis were enrolled in
the control arm and treated by standard STEMI therapy
with primary PCI within 12 hours after symptom onset in
accordance with current guidelines.
Prior to PCI, all patients received 500 mg of aspirin
and activated clotting time-adjusted unfractionated
heparin intravenously. The intake of 100 mg of aspirin
indefinitely plus clopidogrel with a 600 mg loading-dose
reducing to a daily dose of 75 mg for 12 months were
mandatory. All other medication including glycoprotein
IIb/IIIa-inhibitors were administered according to current
guidelines [14]. Primary PCI was performed according to
standard clinical practice. Additional thrombectomy was
used depending on the thrombus burden in the infarct-
related artery.
This study complies with the Declaration of Helsinki
and was approved by the University of Leipzig ethics
committee. All patients gave written informed consent.
Assessment of traditional outcome markers
All patients underwent detailed assessment of medical
history as well as physical examination at index hos-
pitalization. Hypertension, hyperlipidemia, diabetes, and
smoking status were assessed using previous definitions
[15]. Serum creatinine was measured at admission using the
Jaffe method (Roche Diagnostics, Mannheim, Germany).
The TIMI-risk score was calculated for all patients as
previously described [3]. Early ST-segment resolution,
expressed as percentage change from pre to post PCI, was
evaluated by measuring the sum of ST-segment elevation
20 ms after the end of the QRS complex in the electro-
cardiogram before and after PCI [5]. Creatine kinase-MB
(CK-MB) was assessed using the standard photometric
immunological UV-test (Roche Diagnostics, Mannheim,
Germany). Enzymatic infarct size was defined as the
maximum level of CK-MB (CK-MBmax) derived from
measurements every six hours over two days. Pre and post
PCI coronary angiography of the target lesion was per-
formed with the same projections allowing optimal offline
evaluation of the TIMI-flow of the infarct-related artery by
two independent observers [16].
For determination of LV-EFecho all patients underwent
transthoracic examinations 24 to 48 hours after the
index event. An echocardiography was performed by in-
dependent experienced observers according to standard
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of Echocardiography standards using Vivid-7 ultrasound
equipment (GE, Milwaukee, Illinois, United States) [17].
LV-EFecho was assessed in standard apical two- and four-
chamber views capturing at least three cardiac cycles by
using the modified Simpson’s rule.
The time-to-revascularization was calculated in all
patients and was defined as time from symptom onset
or climax of symptoms in case of recurrent pre-infarction
angina to first balloon inflation.
Cardiac magnetic resonance imaging
All patients were examined at rest in the supine position
with a whole body 1.5-Tesla MR scanner (Gyroscan Intera
CV, Philips Medical Systems, Best, Netherlands) equipped
with a five-element cardiac phased-array coil for signal
reception. A vectorcardiogram for gating and triggering
was used. To define the orientation of the heart, a realtime
interactive tool was applied. All images were acquired
during breath-hold at end exspiration.
Assessment of LV-EFCMR was performed by a standard
steady-state free precession technique acquiring short-axis
slices from base to apex as well as horizontal and vertical
long axis views. Delayed enhancement short-axis images
covering the whole ventricle were acquired at the mid-
diastole approximately 15 minutes after the bolus injec-
tion (0.2 mmol/kg/bodyweight) of gadobutrol (Gadovist,
Schering, Leverkusen, Germany). An inversion-recovery
(IR) turbo gradient echo sequence was used for image
acquisition. The individual IR prepulse delay was defined
in order to obtain the maximal contrast between viable
and necrotic myocardium. Short-axis slices covering the
whole left ventricle using a T2-weighted imaging triple
inversion recovery turbo spin-echo sequence before con-
trast administration were obtained, allowing the assess-
ment of edema or area-at-risk.
CMR measurements were performed offline in a core
lab by operators blinded to the baseline and outcome data
using a dedicated CMR evaluation software (View-Forum
release 5.2, Philips Medical Systems, Washington, United
States). A semi-automated computer-aided approach was
used to identify the regions of edema and infarcted myo-
cardium, as previously described [8,18]. Myocardial edema
was defined as a mean signal intensity of more than 2 SD
of remote myocardium in T2-weighted images. The myo-
cardium was considered infarcted if the signal intensity
was more than 5 SD above remote myocardium in delayed
enhancement images. MO was assessed approximately
15 minutes after gadolinium injection, again using delayed
enhancement images. In patients with MO, the areas of
hypo-enhancement within the hyper-enhanced infarct
region were included for infarct size analysis. Infarct size,
area-at-risk, and MO were expressed as percentages of the
left ventricular mass (%LV), given by the sum of the massof edema, late enhancement, and MO regions for all slices
divided by the sum of the LV myocardial cross-sectional
mass. MSI was calculated as area-at-risk minus infarct size
divided by area-at-risk as described previously [19].
LV-EFCMR was calculated from the short-axes functional
views. The performance of the CMR core lab has been
demonstrated previously [20,21].
Endpoints and definitions
Clinical follow-up was conducted via a structured question-
naire by telephone. Any clinical event was verified by hos-
pital charts, direct contact with the treating physician, or
contact with the local government registration. The follow-
up interviewer was not aware of baseline or CMR data. All
outcomes were adjudicated by a clinical events committee.
The primary endpoint was defined as any major adverse
cardiovascular event (MACE) including death, non-fatal
myocardial reinfarction, or congestive heart failure. The
key secondary endpoint was death. Death was regarded as
cardiac in origin unless obvious non-cardiac causes could
be identified. The diagnosis of reinfarction during the
index hospitalization was based on clinical symptoms,
new ST-segment changes, and an increase in the CK-MB
levels above the reference limits in patients with normal-
ized values or if there was an increase of more than 20%
from the last non-normalized measurement. At follow-up,
any new ischemic symptoms leading to hospital admission
accompanied by elevated troponin T was defined as a
reinfarction [22]. New congestive heart failure was defined
as congestive heart failure (= rales, dyspnea, New York
Heart Association functional class III to IV) requiring
medical attention and treatment with diuretics occurring
more than 24 hours after the index event. In patients
experiencing more than one event, the first event was
chosen for the combined clinical endpoint. When one or
more events occurred simultaneously, the most severe
event was chosen (death, followed by reinfarction, followed
by congestive heart failure).
Statistical analysis
Each categorical variable is expressed as the number and
percentage of patients. Continuous data are reported as
medians with the corresponding interquartile range (IQR).
Two-group comparisons were performed with Chi-square
tests for categorical variables, Student t tests for normally
distributed continuous variables and Wilcoxon rank-sum
tests for non-normally distributed continuous variables.
The correlation of enzymatic infarct size and infarct size
assessed by CMR, as well as of LV-EFecho, and LV-EFCMR,
were assessed by Spearman’s correlation coefficients.
Further, univariable and multivariable Cox regression
analyses with stepwise inclusion were performed including
all parameters as continuous variables to investigate the re-
lation of traditional outcome markers and CMR parameters
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ity. All variables with a P value <0.05 in univariable analysis
entered the multivariable model. Finally, C-statistics ac-
cording to DeLong [23] were performed to analyze the
prognostic value in predicting MACE and mortality of a
model including only traditional outcome parameters
(CK-MBmax, TIMI-risk score, ST-segment resolution,
TIMI-flow pre-PCI, TIMI-flow post-PCI, LV-EFecho) when
compared with a second model including CMR parame-
ters (LV-EFCMR, infarct size, MO, and MSI) on top of the
first model [23].
All statistical tests were performed with SPSS software,
version 17.0 (SPSS Inc., Chicago, Illinois, United States)
and MedCalc software, version 12.2.1 (MedCalc Software,
Ostend, Belgium). All probability values were two-tailed
with α = 0.05 and all confidence intervals (CI) were calcu-
lated to the 95th percentile.
Results
Of 512 eligible consecutive patients undergoing primary
PCI for STEMI, CMR was conducted in 438 patients.Table 1 Baseline characteristics and CMR parameters of the wh
Variable All patients (n = 278)
Age, years 65 (55–73)
Male sex, n (%) 201 (72.3)
Hypertension, n (%) 190 (68.6)
Diabetes mellitus, n (%) 74 (26.7)
Hyperlipidemia, n (%) 88 (31.8)
Current smoking, n (%) 104 (37.5)
Serum creatinine, μmol/l 80 (68–91)
BMI, kg/m2 27 (25–30)
CK-MBmax, μmol/l 3.0 (1.4–5.2)
TIMI-risk score 3.0 (2.0–5.0)
ST-segment resolution, % 73 (50–100)
Angiographic findings, n (%)
TIMI-flow pre-PCI 0 147 (52.8)
TIMI-flow pre-PCI I-III 131 (47.1)
TIMI-flow post-PCI 0-II 36 (12.9)
TIMI-flow post-PCI III 242 (87.0)
LV-EFecho, % 45 (40–50)
Time-to-revascularization, min 193 (132–348)
CMR parameters
LV-EFCMR, % 52 (42–60)
Infarct size, %LV 16.1 (8.2–26.6)
MO, %LV 0.69 (0.1–1.6)
MSI 48.0 (27.3–73.5)
Continuous data are presented as median and interquartile range. %LV = percentag
of creatine kinase-MB; CMR = cardiac magnetic resonance imaging; LV-EFCMR = left v
fraction assessed by echocardiography; MACE =major adverse cardiac events; MO =
coronary intervention; TIMI = Thrombolysis In Myocardial Infarction. Traditional outcThe reasons for a lack of CMR were claustrophobia
(n = 19), death prior to CMR (n = 18), refusal (n = 15),
pacemaker (n = 5), obesity (n = 7) and reasons that
could not be further clarified (n = 10). Due to a prior
myocardial infarction, 29 additional patients were exclu-
ded. T2-weighted imaging covering the whole left ven-
tricle was performed in 287 patients. T2-weighted images
of 29 patients were of poor quality, but judged to be
analyzable. Finally, follow-up was completed in 278 (97%)
patients.
Baseline characteristics
Baseline characteristics are displayed in Table 1. CMR
was performed in median three days after the index
event (IQR two to four). Within the follow-up period of
19 months (IQR 10 to 24), 52 events occurred (death
n = 18, reinfarction n = 17, and new congestive heart fail-
ure n = 17 patients). LV-EFecho and LV-EFCMR, as well as
enzymatic infarct size and infarct size assessed by CMR,
were shown to be only moderately correlated (r = 0.63,
P <0.001 and r = 0.69, P <0.001 respectively).ole study cohort and according to the occurrence of MACE
MACE + (n = 52) MACE – (n = 226) P value
69 (60–77) 64 (55–72) 0.02
36 (69.2) 164 (72.9) 0.27
39 (75.0) 224 (67.0) 0.29
21 (40.4) 53 (23.7) 0.04
21 (40.4) 66 (29.5) 0.20
14 (26.9) 89 (39.7) 0.17
83 (69–99) 79 (68–90) 0.18
27 (26–30) 27 (25–30) 0.80
4.5 (1.6–6.7) 2.8 (1.6–5.0) <0.001
5.0 (3.0–7.0) 3.0 (2.0–5.0) <0.001
62 (32–77) 76 (50–100) 0.003
33 (63.4) 115 (50.9) 0.03
19 (36.5) 111 (49.1)
39 (75.0) 23 (10.6) 0.002
13 (25.0) 203 (89.8)
40 (32–50) 46 (40–55) 0.001
211 (135–396) 190 (128–336) 0.35
41 (33–50) 54 (45–62) <0.001
31.5 (22.5–40.0) 13.1 (5.7–22.4) <0.001
1.5 (0.6–2.9) 0.6 (0.0–1.5) 0.001
27.0 (10.0–;39.7) 67.4 (47.9–83.3) <0.001
e of left ventricular mass; BMI = body mass index; CK-MBmax = maximum level
entricular ejection fraction assessed by CMR; LV-EFecho = left ventricular ejection
microvascular obstruction; MSI = myocardial salvage index; PCI = percutaneous
ome markers and prognosis
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curred displayed significantly lower values of ST-segment
resolution, higher levels of CK-MBmax, higher prevalence
of TIMI-flow pre-PCI 0, and lower prevalence of TIMI-
flow post-PCI III in comparison to patients remaining
event-free (Table 1). Finally, the TIMI-risk score was sig-
nificantly higher in patients who experienced an event,
whereas LV-EFecho was significantly lower.
The results of the univariable Cox regression analyses
on the association of traditional outcome markers with
the occurrence of MACE and mortality are displayed in
Tables 2 and 3.
CMR parameters and prognosis
Patients with MACE had a significantly larger infarct
size, higher extent of MO, and lower values of MSI, as
well as a lower LV-EFCMR (Table 1). LV-EFCMR, infarct
size, MO, and MSI were significantly associated with the
time-dependent occurrence of MACE and mortality in
univariable analysis (Tables 2 and 3).
In stepwise multivariable Cox regression analyses,
MSI was identified as an independent predictor for
the time-dependent occurrence of MACE and mortality
(Tables 2 and 3). C-statistics analyzing the prognostic
value to predict MACE and mortality of a model including
only traditional outcome markers (model 1: CK-MBmax,
TIMI-risk score, ST-segment resolution, TIMI-flow pre-
PCI, TIMI-flow post-PCI, and LV-EFecho) to a model
including CMR parameters on top of the traditionalTable 2 Traditional outcome markers and CMR parameters: asso
Cox regression analysis
Univariable analy
Variable HR (95% CI)
Male gender 0.97 (0.53–1.77)
Hyperlipidemia 1.42 (0.82–2.47)
Serum creatinine, μmol/l 1.01 (0.99–1.02)
CK-MBmax, μmol/l 1.02 (1.01–1.03)
TIMI-risk score 1.27 (1.15–1.41)
ST-segment resolution, % 0.98 (0.97–0.99)
TIMI-flow pre-PCI 0 1.24 (1.01–1.53)
TIMI-flow post-PCI 0-II 2.49 (1.44–4.31)
LV-EFecho, % 0.95 (0.92–0.97)
Time-to-revascularization, min 1.00 (0.99–1.01)
LV-EFCMR, % 0.96 (0.94–0.97)
Infarct size, %LV 1.07 (1.05–1.09)
MO, %LV 1.16 (1.07–1.25)
MSI 0.93 (0.92–0.95)
%LV = percentage of left ventricular mass; CK-MBmax = maximum level of creatine k
HR = hazard ratio; LV-EFCMR = left ventricular ejection fraction assessed by CMR; LV-E
MACE =major adverse cardiac events; MO=microvascular obstruction; MSI =myocar
In Myocardial Infarction.outcome markers (model 2: model 1 + LV-EFCMR, infarct
size, MO, and MSI) demonstrated an incremental prognos-
tic value of CMR parameters above traditional outcome
markers (MACE: 0.74 versus 0.94, P <0.001; mortality: 0.69
versus 0.90, P = 0.008, Figures 1 and 2).
Discussion
The main findings of this study can be summarized
as follows: 1) infarct size, MO and MSI as well as
LV-EFCMR are associated with the time-dependent occur-
rence of death, reinfarction and congestive heart failure
after STEMI; 2) MSI is a strong independent predictor for
MACE and mortality; and 3) CMR parameters such as
infarct size, MO, MSI, and LV-EFCMR add incremental
prognostic value above traditional outcome markers only.
Although in recent years substantial progress with regard
to short-term outcome has been made in patients with
STEMI, longterm prognosis has not been significantly
altered and remains unsatisfactory despite the implementa-
tion of new primary and secondary prevention strategies
[1]. Thus, increasing emphasis has been put on optimized
risk stratification, as this offers the potential to further
improve outcome by identifying patients who are at high
risk. In clinical routine this is mainly performed by elec-
trocardiographic and echocardiographic tests, as well as
laboratory and angiographic parameters or established risk
scores [2-5]. In contrast to these indirect markers of
reperfusion success, CMR offers the possibility to directly
visualize and quantify infarct expansion and microvascularciation with MACE in univariable and stepwise multivariable
sis Multivariable analysis
P value HR (95% CI) P value
0.97 not included -
0.21 not included -
0.23 not included -
0.01 - -
<0.001 - -
0.001 - -
0.04 - -
0.001 - -
<0.001 - -
0.44 not included -
<0.001 - -
<0.001 - -
<0.001 - -
<0.001 0.94 (0.92–0.96) <0.001
inase-MB; CI = confidence interval; CMR = cardiac magnetic resonance imaging;
Fecho = left ventricular ejection fraction assessed by echocardiography;
dial salvage index; PCI = percutaneous coronary intervention; TIMI = Thrombolysis
Table 3 Traditional outcome markers and CMR parameters: association with mortality in univariable and stepwise
multivariable Cox regression analysis
Univariable analysis Stepwise multivariable analysis
Variable HR (95% CI) P value HR (95% CI) P value
Male gender 1.24 (0.42–3.60) 0.70 not included -
Hyperlipidemia 0.81 (0.29–2.27) 0.69 not included -
Serum creatinine, μmol/l 1.01 (0.98–1.03) 0.64 not included -
CK-MBmax, μmol/l 1.04 (0.99–1.08) 0.08 - -
TIMI-risk score 1.31 (1.07–1.60) 0.009 - -
ST-segment resolution, % 0.99 (0.98–1.01) 0.07 not included -
TIMI-flow pre-PCI 0 1.20 (0.83–1.75) 0.32 not included -
TIMI-flow post-PCI 0-II 4.39 (1.73–11.15) 0.002 - -
LV-EFecho, % 0.94 (0.89–0.98) 0.005 - -
Time-to-revascularization, min 1.00 (0.99–1.01) 0.25 not included -
LV-EFCMR, % 0.95 (0.92–0.98) 0.003 - -
Infarct size, %LV 1.07 (1.04–1.10) <0.001 - -
MO, %LV 1.09 (1.02–1.21) 0.01 - -
MSI 0.93 (0.92–0.95) <0.001 0.93 (0.90–0.95) <0.001
%LV = percentage of left ventricular mass; CI = confidence interval; CK-MBmax = maximum level of creatine kinase-MB; CMR = cardiac magnetic resonance imaging;
HR = hazard ratio; LV-EFCMR = left ventricular ejection fraction assessed by CMR; LV-EFecho = left ventricular ejection fraction assessed by echocardiography;
MO =microvascular obstruction; MSI = myocardial salvage index; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction.
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dium. Previous mid-sized single center studies have shown
that all of these CMR parameters of myocardial damage
are associated with adverse functional and clinical outcome
[6-9]. CMR parameters might therefore present a powerful
tool for detecting patients at the highest risk of a recurrent
cardiovascular event. To date, there are few data on theFigure 1 C-statistics comparing the prognostic value for MACE
prediction of model 1 (CK-MBmax, TIMI-risk score, ST-segment
resolution, TIMI-flow pre-PCI, TIMI-flow post-PCI, LV-EFecho) and
model 2 (model 1 + LV-EFCMR, infarct size, MO and MSI).potential incremental value of CMR parameters above
traditional outcome markers. Given the high cost of CMR,
evidence of such additional prognostic value would be a
prerequisite for a more widespread use of CMR in the
assessment of prognosis outside the research setting.
However, previous studies analyzing the prognostic valueFigure 2 C-statistics comparing the prognostic value for
mortality prediction of model 1 (CK-MBmax, TIMI-risk score,
ST-segment resolution, TIMI-flow pre-PCI, TIMI-flow post-PCI,
LV-EFecho) and model 2 (model 1 + LV-EFCMR, infarct size, MO
and MSI).
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complete inclusion of traditional outcome markers [6-9].
Further, these studies led to inconsistent results. In detail,
Larose et al. identified infarct size as the best predictor for
adverse outcome in comparison to traditional prognostic
markers [9]. However, parameters such as established clin-
ical risk scores, ST-segment resolution or post-procedural
angiographic results were not included. When interpreting
these data it is important to mention that MSI was
assessed by acquiring only three slices of T2-weighted im-
ages to identify the area-at-risk and/or edema, which might
have significantly influenced the results [9]. In addition, the
combined endpoint included relatively weak components
such as LV-EF of less than 35% at follow-up. Finally, the
study cohort comprised of only 103 patients. In contrast,
Masci et al. could identify MSI as an independent pre-
dictor for adverse functional outcome and ST-segment
resolution [24]. In line with these results, Eitel et al.
demonstrated a clear independent association of MSI with
adverse clinical outcome in 208 patients [7,8]. However, in
these studies, adjustment for a broad spectrum of trad-
itional outcome markers was not performed. The assess-
ment of LV-EF and infarct size can be conducted by
alternative methods such as transthoracic echocardiog-
raphy and laboratory analysis of cardiac enzymes. Both
parameters are known to have a high prognostic impact
and represent clinical standard, requiring only moderate
financial and personnel resources in comparison to the
rather complex assessment of infarct size and LV-EF by
CMR. Besides LV-EFecho and enzymatic infarct size, the
TIMI-risk score is also known to be a strong predictor for
clinical outcome and its assessment can be easily perfor-
med within the daily clinical routine requiring virtually no
additional expense. Nevertheless, the prognostic value of
CMR parameters including MSI has so far never been
compared to this well-validated clinical risk score. Thus,
the current study expands on previous findings as we could
demonstrate that MSI is a strong independent predictor
for MACE and mortality even after adjustment for a
detailed and comprehensive set of traditional prognostic
parameters.
Moreover, the current study is the first to demonstrate
that CMR parameters offer incremental prognostic value
for MACE and mortality in addition to the methods
for risk stratification commonly performed in clinical
routine. Although infarct size, MO, or MSI have not
directly been linked to differing treatment strategies,
they offer the potential to identify patients requiring
more intensive medical care in the subacute and chronic
phase after STEMI. Finally, in the light of the prognostic
value, the current results underline the role of CMR pa-
rameters as surrogate endpoints for clinical trials apart
from further risk stratification in clinical patient-based
routine.Some limitations of the current trial need to be ad-
dressed. First, these data arise from a single-center cohort
and the sample size is still too small to reach definitive
conclusions; however, it is the largest cohort reported so
far. Second, CMR data were acquired during the first days
after STEMI with some heterogeneity between the indi-
vidual examinations. Although data on the natural evolu-
tion of infarct size, MO, and MSI after STEMI are scarce
and ambiguous, performing CMR at a singular exact time
point after STEMI might lead to the most accurate results.
Third, CMR image analysis was performed using a semi-
automated approach. Alternative methods exist including
the full width at half maximum technique or manual de-
lineation. However, the optimal technique for CMR image
analysis has not yet been established [25]. In addition, the
threshold for the determination of infarcted myocardium
used in the current analysis is in line with the recom-
mendation of the Society of Cardiovascular Magnetic
Resonance for semi-automated analysis in myocardial
infarction [25]. Moreover, as the different techniques have
been shown to yield comparable results, one does not
have to anticipate substantially different results due to dif-
fering techniques [26-28]. Further, LV-EFecho and LV-
EFCMR were assessed at different time-points, as patients
underwent echocardiography between 24 and 48 hours
after the index event, whereas CMR was performed at a
median of 72 hours post-reperfusion. Further, assessment
of LV-EF using echocardiography is based on geometrical
assumptions which lead to less robust results in the pres-
ence of regional contractility abnormalities, which is often
the case after STEMI. Thus, the difference in LV-EFecho
and LV-EFCMR can be most likely explained by the differ-
ing techniques and subsequent differing accuracy and
slight changes of LV function during the first days after
STEMI. In addition, we used CK-MBmax to assess enzym-
atic infarct size, although troponin would have been a
good alternative [29-31]. Nevertheless it is unlikely that
the inclusion of troponin instead of CK-MBmax would
have resulted in a significant change in the results as the
prognostic value of CK-MBmax and its correlation with
troponin is well-established [32-34]. Moreover, numerous
other parameters assessed by CMR, echocardiography,
angiography, laboratory analysis, or functional exami-
nations including right ventricular function, concomitant
valve disease, coronary collateralization, N-terminal pro
brain natriuretic peptide, or exercise capacity could have
been included in the current study. However, from a stat-
istical point of view the analyzable number of parameters
should be limited according to sample size and number of
events during follow-up. Thus, to conserve an acceptable
statistical robustness of the model, we decided to limit our
analysis to the best-validated CMR parameters and the
most commonly used prognostic markers assessed in
clinical routine.
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ior prognostic value of MSI in comparison to other CMR
parameters, we cannot elucidate the exact mechanisms
linking MSI to adverse clinical outcome, as data on the
pathophysiological mechanism behind why MSI is a stron-
ger predictor for adverse clinical outcome than MO or
infarct size are scarce. Potential explanations are, for
example that individual patient characteristics lead to less
MSI and likewise influence adverse clinical outcome such
as endothelial function or sensitivity to ischemic pre- and
post-conditioning; a higher rate of transmural infarctions
and less reduction of infarct size in the months following
the index event, in the presence of less MSI, lead to worse
functional outcome and substrates for malignant arrhyth-
mias independent of the infarct size itself; or that there is
higher local and systemic inflammation in the presence of
less MSI. Although theoretically many potential links of
MSI with clinical outcome are conceivable, these remain
speculative and cannot be fully confirmed by results of
basic research. However, despite missing pathophysio-
logical data on the association of MSI and clinical out-
come, its prognostic value has been clearly demonstrated
in this observational study.
Conclusions
CMR parameters such as infarct size, MO, MSI, and
LV-EFCMR, add incremental prognostic value above
the assessment of traditional risk markers alone. This
allows improved identification of patients at high risk
for adverse late outcome and could potentially help to
optimize clinical management and subsequent outcome in
these patients.
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